Trade Zai Lab Limited - ZLAB CFD
Add to favourite- Summary
- Historical Data
Spread | 0.26 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 18.79 |
Open | 18.88 |
1-Year Change | -37.55% |
Day's Range | 18.52 - 19.37 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 18.72 | 0.04 | 0.21% | 18.68 | 19.15 | 18.45 |
Jul 24, 2024 | 18.96 | 0.06 | 0.32% | 18.90 | 19.22 | 18.83 |
Jul 23, 2024 | 19.32 | 0.19 | 0.99% | 19.13 | 19.51 | 19.02 |
Jul 22, 2024 | 19.60 | 0.93 | 4.98% | 18.67 | 20.04 | 18.67 |
Jul 19, 2024 | 18.57 | 0.41 | 2.26% | 18.16 | 18.71 | 17.96 |
Jul 18, 2024 | 18.70 | 0.02 | 0.11% | 18.68 | 19.36 | 18.56 |
Jul 17, 2024 | 18.62 | 0.53 | 2.93% | 18.09 | 18.84 | 17.96 |
Jul 16, 2024 | 18.51 | 0.61 | 3.41% | 17.90 | 18.79 | 17.78 |
Jul 15, 2024 | 17.94 | 0.15 | 0.84% | 17.79 | 18.13 | 17.42 |
Jul 12, 2024 | 17.93 | 0.02 | 0.11% | 17.91 | 18.78 | 17.78 |
Jul 11, 2024 | 17.78 | 0.76 | 4.47% | 17.02 | 17.85 | 16.97 |
Jul 10, 2024 | 16.95 | 0.54 | 3.29% | 16.41 | 17.25 | 16.41 |
Jul 9, 2024 | 16.53 | 0.08 | 0.49% | 16.45 | 16.73 | 16.09 |
Jul 8, 2024 | 16.89 | 0.10 | 0.60% | 16.79 | 17.27 | 16.78 |
Jul 5, 2024 | 17.22 | 0.08 | 0.47% | 17.14 | 17.52 | 16.95 |
Jul 3, 2024 | 17.17 | -0.09 | -0.52% | 17.26 | 17.65 | 17.10 |
Jul 2, 2024 | 17.31 | 0.40 | 2.37% | 16.91 | 17.31 | 16.81 |
Jul 1, 2024 | 17.24 | 0.08 | 0.47% | 17.16 | 17.88 | 16.91 |
Jun 28, 2024 | 17.27 | 0.32 | 1.89% | 16.95 | 17.48 | 16.74 |
Jun 27, 2024 | 17.45 | 0.27 | 1.57% | 17.18 | 17.81 | 17.09 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Zai Lab Limited Company profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.Industry: | Biopharmaceuticals |
4560 Jinke Road
Bldg. 1, 4/F
SHANGHAI
SHANGHAI 201210
CN
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com